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ABSTRACT
The outstanding characteristics of circulatory microRNAs (miRNAs) attract much 
attention in research on disease biomarkers and disease pathogenesis. This study 
aimed to identify the expression profiles of plasma miRNAs in patients with rheumatoid 
arthritis (RA). Thirty-three miRNAs were screened using an miRNA array, of which 
9 miRNAs were validated as differentially expressed in the plasma of RA patients 
compared with healthy controls (HCs). miRNA-4634 (miR-4634), miR-181d and miR-
4764-5p expression levels were increased, whereas miR-342-3p, miR-3926, miR-
3925-3p, miR-122-3p, miR-9-5p and miR-219-2-3p expression levels were decreased 
in RA patients. The areas under the curve (AUCs) were generated to estimate the 
sensitivity and specificity of each miRNA or the panel of all 9 miRNAs as biomarkers 
for RA. AUCs for 9 individual miRNAs ranged from 0.6254 to 0.818; however, the AUC 
for the panel of 9 miRNAs reached 0.964. Levels of miR-122-3p, miR-3925-3p, miR-
342-3p and miR-4764-5p expression showed significant differences between RA and 
other control groups. miR-4764-5p, miR-4634, miR-9-5p and miR-219-2-3p exhibited 
significant correlations with either plasma cytokine and chemokine levels or clinical 
features. In conclusion, this study identified 9-plasma miRNAs signature in Chinese 
patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
INTRODUCTION
MicroRNAs (miRNAs) are small non-coding 
RNAs that have critical functions in a wide range of 
biological and pathologic processes [1, 2]. Recent studies 
demonstrated that miRNAs are exported from cells and 
are detected in the circulation including in serum, plasma, 
urine, saliva and other body fluids [3, 4]. Surprisingly, 
these circulatory miRNAs are well-protected from 
endogenous RNase activity and show a remarkable 
stability even under harsh conditions, including boiling, 
low/high pH, extended storage, and freeze-thaw cycles. 
Moreover, alterations in the expression of circulatory 
miRNAs have been associated with several diseases, 
such as cancers [5-8], autoimmune diseases [9-11] and 
tissue injury [12]. These outstanding characteristics of 
circulatory miRNAs have attracted much attention in 
disease biomarker and pathogenesis research.
Rheumatoid arthritis (RA) is a chronic inflammatory 
autoimmune disease of the synovial joints that is 
characterized by leukocyte infiltration and synoviocyte 
activation, which lead to cartilage and bone destruction 
[13, 14]. Recent studies have supported an important role 
for miRNAs in RA: aberrant miRNA expression has been 
detected in different cell types in RA, and these miRNAs 
regulate specific pathways involved in RA pathogenesis 
[15-19]. In contrast to cellular or tissue miRNAs, the 
expression profile of circulatory miRNAs in RA has not 
been fully investigated. Koichi Murata et al. selected 5 
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miRNAs and reported that plasma miR-132 differentiated 
healthy controls (HCs) clearly from patients with RA 
or osteoarthritis (OA), whereas synovial fluid miRNAs 
differentiated RA from OA [20]. In their subsequent report, 
using a TaqMan miRNA array containing 768 miRNAs, 
plasma miR-24 and miR-125a-5p were identified as 
potential biomarkers for RA [21]. 
In recent years, a growing body of new miRNAs 
has been identified, which provides new candidates for 
the screening of biomarkers of autoimmune diseases, 
including RA. In this study, we used the miRCURY™ 
LNA Array (v.18.0), a 7th-generation miRNA array 
containing 3100 capture probes, to evaluate the expression 
profiles of plasma miRNAs in Chinese RA patients and 
HCs. Nine plasma miRNAs were found to be differentially 
expressed which may serve as noninvasive biomarkers for 
the diagnosis of RA and their correlations with plasma 
cytokine, chemokine and clinical features may contribute 
to the further understanding of RA pathogenesis. 
RESULTS
Study population
 During the screening phase, 5 RA patients and 5 
HCs were enrolled, and the characteristics of these study 
participants are presented in Table 1. The clinical features 
of the RA patients (n = 75) and HCs (n = 70) enrolled in 
the selection and validation sets are presented in Table 2. 
There was no significant difference in the distribution of 
age or gender between the RA and HC groups enrolled for 
screening, selection or validation. 
miRNA profiling in RA patients vs. HCs using the 
miRCURY™ LNA array
The miRCURY™ LNA Array (v.18.0), a 7th-
generation miRNA array containing 3100 capture probes, 
was used to evaluate plasma miRNA expression profiles 
in RA patients and HCs. Each plasma sample from the 
enrolled RA patients and HCs (n = 5 each) was tested 
individually rather than pooling the samples, as is 
typically done. A total of 138 miRNAs (fold change ≥1.5) 
were up-regulated in RA, whereas 187 (fold change ≥1.5) 
were down-regulated. To identify differentially expressed 
miRNAs that were statistically significantly different, we 
performed Volcano-Plot filtering using data from the RA 
patients and HCs. The threshold used to screen up- or 
down-regulated miRNAs was a fold change ≥1.5 together 
with a P-value ≤0.05. Based on these criteria, 22 miRNAs 
were up-regulated and 11 miRNAs were down-regulated 
in RA plasma (see S1 Table). These 33 differentially 
expressed miRNAs between RA and HCs are shown as a 
Figure 1: Overview of the experimental strategy. RA, rheumatoid arthritis; HCs, healthy controls; RT-PCR, reverse transcriptase 
polymerase chain reaction; ROC, receiver operating characteristics.
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Figure 2: ROC curves showing the ability of the plasma concentrations of the 9 individual miRNAs (A-I) and the 
9-miRNA panel (J) to differentiate the RA cases (n = 75) from the controls (n = 70).
Table 1: Clinical features of the RA patients and the HCs enrolled for 
the miRCURY™ LNA Array study.
Characteristics RA HCs
Number of participants
Gender, male/female 
Age, mean (range) 
RF titer (IU)
ESR (mm), mean (range) 
CRP (mg/dl), mean (range) 
DAS28, mean (range) 
SJC, mean (range) 
TJC, mean (range)
5
0/5
45.4(33 to 64)
202.56
25(12 to 37)
12.36(1.46 to 26.3)
5.16(4.16 to 6.82)
19(10 to 28)
13(0 to 22)
5
0/5
43.8(30 to 65)
NA
NA
NA
NA
NA
NA
CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, 
erythrocyte sedimentation ratio; NA, not applicable; SJC, swollen joint 
count; TJC, tender joint count.
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heat map and using hierarchical clustering based on the Cq 
value of each miRNA (see S1 Figure).
Validation of the array result by RT-PCR
To validate the array result, the 33 differentially 
expressed miRNAs screened by miRNA array were first 
selected in a small set of individual plasma samples (14 
RAs and 18 HCs, selection phase) by qRT-PCR. miRNAs 
with a Cq value > 35 were excluded, and only miRNAs 
with a ≥1.5-fold mean change together with a P-value 
≤0.05 were selected for further validation. Using these 
criteria, 22 differentially expressed miRNAs were selected 
(data not shown). Subsequently, the 22 selected miRNAs 
were further quantified in a larger cohort consisting of an 
independent set of individual plasma samples (75 RA and 
70 HCs, validation set). As shown in Table 3, the levels 
Figure 3: Evaluation of the validated 9 miRNAs for the discrimination of active RA from non-active RA. RA patients 
were divided into two groups: the active group (n = 44) and the non-active group (n = 31) based on DAS28. The bars denote the mean 2-Δcq 
values ± SD (*, P-values < 0.05 versus HCs; **, P-values < 0.01 versus HCs).
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of three miRNAs, miR-4634, miR-181d and miR-4764-
5p, were significantly increased, whereas the levels of six 
miRNAs, miR-342-3p, miR-3926, miR-3925-3p, miR-
122-3p, miR-9-5p, miR-219-2-3p, were significantly 
decreased in RA patients compared with HCs. For both 
the selection and validation phases, spike-in cel-miR-39 
and cel-miR-238 were used for normalization.
Evaluation of the validated 9 miRNAs as 
biomarkers for the diagnosis of RA
To evaluate the potential application of the 9 
miRNAs screened as biomarkers for RA, we generated 
ROC curves to estimate the sensitivity and specificity of 
each miRNA or the panel of all 9 miRNAs. As shown in 
Figure 2, the AUCs for 9 miRNAs ranged from 0.6254 to 
0.818. Logistic regression was also used to evaluate the 
diagnostic value of the combination of the 9 miRNAs as 
a panel. The ROC curve for the 9-miRNA panel revealed 
a high diagnostic accuracy (AUC, 0.964; 95% confidence 
interval [CI], 0.932 - 0.997; P < 0.0001), which was better 
than that of the individual miRNAs. These results suggest 
that the combination of the 9 miRNAs in a panel shows 
great potential as a biomarker for discriminating RA 
patients from HCs.
Evaluation of the validated 9 miRNAs for the 
discrimination of active RA from non-active RA
To further explore the potential usefulness of the 
9 screened miRNAs as a biomarker, we analyzed the 
correlation of these plasma miRNAs with the clinical 
status of the RA patients. The RA patients were divided 
into an active RA group (n = 44) and a non-active group 
(n = 31) based on their DAS28 scores. Probability values 
were calculated using ANOVAs. Unexpectedly, active 
and non-active RA patients showed similar changes in 
expression of the 9 validated miRNAs compared with 
HCs. None of the 9 validated plasma miRNAs were 
differentially expressed between active and non-active 
RA (Figure 3). Our results suggest that these 9 validated 
plasma miRNAs are not suitable biomarkers for the 
discrimination of active vs. non-active RA. 
Table 2: Clinical features of the RA patients and HCs enrolled in the selection and validation sets.
Characteristics RA(active) RA(non-active) HCs
Number of participants
Gender, male/female 
Age, mean (range) 
RF titer (IU)
ESR (mm), mean (range) 
CCP-Ab, mean (range)
CRP (mg/dl), mean (range) 
DAS28, mean (range) 
SJC, mean (range) 
TJC, mean (range)
44
6/38
53.3(24 to 75)
332.7(8 to 1450
49.24(2 to 319)
275.28(20 to 942.7)
13.6(1 to 55.3))
5.8(3.51 to 7.58)
7.8(2 to 20)
13.1(2 to 28)
31
5/26
51.54(22 to 81)
237.2(4 to 2560)
28.48(4 to 250)
335.44(8 to 768)
9.2(1 to 64.7)
2.1(1.18 to 3.18)
0.038(0 to 1)
0.21(0 to 2) 
70
6/64
46.67(26 to 68)
NA
NA
NA
NA
NA
NA
NA
RA, rheumatoid arthritis; HCs, healthy controls; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, 
erythrocyte sedimentation ratio; NA, not applicable; SJC, swollen joint count; TJC, tender joint count.
Table 3: Differentially expressed miRNAs in the validation set determined using qRT-PCR (containing samples used 
in the selection phase).
Gene symbol Rank Parametric P-value HCs (n = 70 ) RA (n = 75)
Fold-
change
Up-
regulated
hsa-miR-4634 1 0.0118 10.01 4.358 2.297
hsa-miR-181d 2 0.0201 4.060 1.686 2.408
hsa-miR-4764-5 p 3 0.0299 15.12 29.69 1.964
Down-
regulated
hsa-miR-342-3p 1 0.0001 2.310 0.5078 0.2198
hsa-miR-3926 2 0.0001 6.891 1.182 0.1715
hsa-miR-3925-3p 3 0.0001 0.8896 0.04146 0.04661
hsa-miR-122-3p 4 0.0207 13.27 2.729 0.2057
hsa-miR-9-5p 5 0.0223 7.625 21.32 0.2796
hsa-miR-219-2-3p 6 0.0331 16.18 3.768 0.2329
Ranked by P-values generated from statistical comparisons between RA patients and HCs. In the RA and HCs columns, 
values for the mean of 2-Δcq for each group are listed. Fold-change is the ratio of relative expression of RA vs. HCs.
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Evaluation of the validated 9 miRNAs for the 
discrimination of RA patients from disease 
controls
The expression of 9 validated plasma miRNAs in 
patients with RA (n = 75, containing 44 active RA and 31 
non-active RA patients) together with those from disease 
controls was also analyzed (Figure 4). 4 miRNAs showed 
highly significant differentiation between patients with RA 
and three groups of patients with other disease (OA, SLE, 
Graves’ disease), in which the expression levels of miR-
122-3p and miR-3925-3p were down-regulated while miR-
342-3p and miR-4764-5p were up-regulated. In addition, 
miR-9-5p and miR-181d significantly discriminated the 
RA group from both SLE and Graves’ disease groups but 
not the OA group. Moreover, miR-219-2-3p differentiated 
the RA group from the OA group but not SLE and Graves’ 
disease group. Furthermore, miR-3926 could discriminate 
the RA group from the SLE group but not the OA and 
Graves’ disease group. However, the expression levels 
of miR-4634 of RA patients did not show any significant 
differences from disease controls.
Correlation between the 9 validated plasma 
miRNAs and the plasma cytokine and chemokine 
levels in RA
We next quantitatively measured the plasma 
cytokine and chemokine levels to assess their relationship 
to the 9 validated plasma miRNAs using Pearson’s 
correlation analyses. The cytokines and chemokines 
measured were IL-6, IFN-γ, IL-1β, TNF-α, IL-17A, IL-4, 
IL-13, CXCL9, MCP-1, MIP-1α, MIP-1β and IL-8. miR-
9-5p expression correlated positively with plasma levels 
of IFN-γ, TNF-α, IL-17A, IL-4 and CXCL9, whereas 
miR-219-2-3p expression only correlated significantly 
with CXCL9. miR-4764-5p expression was negatively 
correlated with IL-13. No significant correlations of the 6 
other miRNAs with plasma cytokines or chemokines were 
noted in RA patients (see Table 4).
Correlations between the 9 validated plasma 
miRNAs and clinical variables in RA
We also investigated the correlations of the 9 
validated miRNAs with clinical variables, including 
erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), rheumatoid factor (RF), swollen joint count (SJC), 
tender joint count (TJC) and 28-joint Disease Activity 
Table 4: Spearman rank correlations between the differentially expressed plasma miRNAs and cytokine and chemokine 
levels in RA patients (r/P).
Variable miR-9-5p miR-122-3p
miR-219-
2-3P miR-4634 miR-181d
miR-342-
3p
miR-
4764-5p miR-3926
miR-3925-
3p
IL-6 -0.2323p = 0.2343
-0.2187
p = 0.2731
-0.06022
p = 0.7608
-0.03213
p = 0.8711
-0.07789
p = 0.6936
-0.09731
p = 0.6223
-02412
p = 0.2255
-02393
p = 0.2601
0.08707
p = 0.6723
IL-1β 0.2570p = 0.1867
0.1688
p = 0.3906
-0.04032
p = 0.8386
-0.01826
p = 0.9280
0.09281
p = 0.6452
0.1979
p = 0.3127
-0.1579
p = 0.4222
0.06379
p = 0.7619
0.1256
p = 0.5408
TNF-α 0.4143p = 0.0494
0.2376
p = 0.2528
-0.01801
p = 0.9319
0.08805
p = 0.6895
0.07644
p = 0.7165
0.3025
p = 0.1711
-0.1227
p = 0.5679
-0.1345
p = 0.5308
-0.2227
p = 0.2956
IFN-γ 0.4454p = 0.0491
0.2380
p = 0.2861
-0.07470
p = 0.7411
0.07903
p = 0.7405
0.1049
p = 0.0506
0.2283
p = 0.3069
-0.1953
p = 0.3837
0.04103
p = 0.8561
0.1306
p = 0.5625
IL-17A 0.4349p = 0.0431
0.3061
p = 0.1283
0.04851
p = 0.8140
0.1224
p = 0.5514
0.05285
p = 0.7976
0.2599
p = 0.1998
0.02056
p = 0.9206
0.1307
p = 0.5245
0.1656
p = 0.4189
IL-4 0.4158p = 0.0278
0.1952
p = 0.2926
0.00465
p = 0.9802
0.0184
p = 0.9218
0.05747
p = 0.7588
0.1995
p = 0.2821
-0.1361
p = 0.4653
0.09976
p = 0.5934
0.2358
p = 0.2015
IL-13 0.02635p = 0.9027
0.09804
p = 0.6486
-0.2185
p = 0.3051
-0.2185
p = 0.3049
-0.036635
p = 0.8651
0.1089
p = 0.6124
-0.4241
p = 0.0389
-0.1146
p = 0.594
0.0765
p = 0.7224
CXCL9 0.4737p = 0.0009
0.2515
p = 0.0813
0.4055
p = 0.0085
0.2170
p = 0.1341
-0.03866
p = 0.7920
0.03672
p = 0.8022
0.1308
p = 0.3702
-0.1391
p = 0.3404
-0.1939
p = 0.1818
MCP-1 0.1403p = 0.3312
0.04001
p = 0.7827
0.07996
p = 0.5810
-0.02246
p = 0.8770
0.01528
p = 0.9161
0.001168
p = 0.9936
0.07062
p = 0.6262
-0.1317
p = 0.3619
-0.1176
p = 0.4160
MIP-1α 0.1112p = 0.4618
0.1054
p = 0.4859
0.05332
p = 0.7249
0.06869
p = 0.6501
0.01445
p = 0.9241
0.08785
p = 0.5616
0.2341
p = 0.1173
0.06175
p = 0.6835
-0.04892
p = 0.7468
MIP-1β -0.03737p = 0.8009
-0.07583
p = 0.6085
0.09176
p = 0.5351
0.04074
p = 0.7834
0.005932
p = 0.9681
0.03437
p = 0.8166
0.1698
p = 0.2486
0.01821
p = 0.9022
-0.02827
p = 0.08487
IL-8 -0.04628p = 0.7949
-0.05651
p = 0.7509
0.03439
p = 0.8469
0.1248
p = 0.4818
-0.02513
p = 0.8878
0.01337
p = 0.9402
0.2542
p = 0.1468
0.09280
p = 0.6017
0.01076
p = 0.9518
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Score (DAS28). Plasma miR-4634 correlated with all 
clinical features we examined, with the exception of CRP. 
Both miR-4764-5p and miR-219-2-3p correlated with RF, 
SJC, TJC and DAS28, whereas miR-9-5p correlated only 
with RF. Plasma miR-122-3p, miR-181d, miR-342-3p, 
miR-3926 and miR-3925-3p did not correlate with clinical 
parameters (see Table 5).
DISCUSSION
An increasing number of studies have addressed 
the important role of miRNAs in various physiological 
processes and the potential of miRNAs for use in clinical 
biochemistry. Although the utility of circulatory miRNAs 
as biomarkers remains exploratory, an effective diagnostic 
strategy has been developed. First, large-scale miRNA 
profiling (e.g., miRNA microarray, Solexa sequencing 
and miRNA TaqMan low-density arrays) is performed, 
and data are compared between a small group of patients 
with the disease of interest and a control group. miRNAs 
that show significant differences between groups are 
then selected and validated on larger populations using 
individual qRT-PCRs, thereby establishing performance 
parameters, such as sensitivity, specificity and AUCs. Thus 
far, following this strategy, previous miRNA array studies 
have identified many differentially expressed circulatory 
miRNAs as potential biomarkers in various diseases 
including cancers, autoimmune diseases and tissue injury 
[22-28].
In this current study, using an updated miRNA array 
containing 1800 miRNAs that was followed by qRT-PCR 
validation, we observed higher plasma expression of miR-
4634, miR-181d and miR-4764-5p and lower expression 
of miR-342-3p, miR-3926, miR-3925-3p, miR-122-3p, 
miR-9-5p and miR-219-2-3p in Chinese RA patients. A 
previous study by Koichi Murata et al. also performed 
an array-based miRNA analysis of plasma samples from 
Japanese RA patients and HCs and identified increased 
concentrations of plasma miR-24 and miR-125a-5p, 
demonstrating their potential as diagnostic markers of 
RA [21]. There is no overlap in miRNA profiles between 
these two studies. Several reasons may underlie this 
unexpected result: first, the RA populations enrolled in 
these two studies were selected from different countries; 
thus, different genetic backgrounds may contribute 
partially to these differences. Secondly, Koichi Murata 
et al. assessed differential expression of plasma miRNAs 
in RA patients using an miRNA array containing 768 
miRNAs, whereas in our study, we applied a larger array 
database containing 1800 miRNAs. In our study, several 
newly identified miRNAs were screened, although their 
functional characteristics remain unclear. In addition, for 
miRNA array analysis, we selected active RA patients 
who were not receiving clinical treatment rather than RA 
patients who were being treated, as were enrolled in the 
previous study by Murata et al [21]. 
The quantification of cellular or tissue miRNAs 
may be normalized to U6 small nuclear RNA (snRNA); 
however, thus far, there has been no suitable internal 
control for plasma miRNA normalization. The expression 
level of plasma miRNA is typically normalized by 
spiking in exogenous miRNA from Caenorhabditis 
elegans or plants as controls or is based on the volume of 
plasma sample. In this study, we spiked in two synthetic 
Caenorhabditis elegans miRNAs as exogenous controls 
(cel-miR-39 and cel-miR-238), which lacked sequence 
homology to human miRNAs, and we used the mean Cq 
value of these two external miRNAs to normalize plasma 
miRNA expression. This design may help reduce sample-
Table 5: Spearman rank correlations between differentially expressed plasma miRNAs and clinical features in RA 
patients (r/P).
Variable miR-9-5p miR-122-3p miR-219-2-3P
miR-
4634
miR-
181d
miR-342-
3p
miR-
4764-5p miR-3926
miR-3925-
3p
ESR -0.01187p = 0.9355
0.03362
p = 0.8186
0.1900
p = 0.1910
0.4014
p = 
0.0069
0.01802
p = 
0.9022
-0.0084
p = 0.9545
0.07344
p = 0.6160
-0.1236
p = 0.3973
-0.1762
p = 0.2257
CRP 0.05934p = 0.6855
0.09276
p = 0.5261
0.2202
p = 0.1284
0.1985
p = 
0.1715
0.02157
p = 
0.8830
0.05337
p = 0.7157
0.09069
p = 0.5354
-0.08076
p = 0.5812
-0.03299
p = 0.8220
RF 0.4635p = 0.005
0.1408
p = 0.4059
0.412
p = 0.0172
0.4342
p = 
0.0147
0.04564
p = 
0.7885
0.1034
p = 0.5427
0.4699
p = 0.005
0.02072
p = 0.9031
-0.02438
p = 0.8861
SJC -0.06894p = 0.6379
-0.1299
P = 0.3736
0.4158
p = 0.0068
0.5010
p = 
0.0004
0.1824
p = 
0.2098
0.04737
p = 0.7466
0.4239
p = 0.0033
-0.1993
p = 0.1698
-0.1286
p = 0.3784
TJC -0.02733p = 0.7371
-0.1061
p = 0.4682
0.4037
p = 0.0066
0.4282
p = 
0.0027
0.1473
p = 
0.3124
0.1193
p = 0.4141
0.4015
p = 0.0047
-0.1779
p = 0.2215
-0.1274
p = 0.8330
DAS28 -0.01414p = 0.9232
-0.06479
p = 0.6583
0.4358
p = 0.0068
0.5147
p = 
0.0003
0.1224
p = 
0.4023
0.01561
p = 0.9152
0.4228
p = 0.0028
-0.2504
p = 0.0827
-0.2238
p = 0.1222
Oncotarget42564www.impactjournals.com/oncotarget
to-sample variations. Although successful real-time RT-
PCR technologies have been developed to amplify and 
quantify miRNAs, to apply plasma miRNAs as biomarkers 
in the clinical setting, it will be necessary to develop 
practical clinical assays that incorporate RNA extraction, 
primer design and normalization controls. 
In this study, we identified a total of 9 miRNAs that 
were differentially expressed in the plasma of RA patients 
and HCs. Subsequently, we evaluated the potential of 
using these 9 miRNAs as diagnostic markers for RA. 
ROC curves were used to estimate the sensitivity and 
specificity of each miRNA. The AUCs for the 9 individual 
miRNAs ranged from 0.6254 to 0.818; however, the 
AUCs for the panel of the 9 miRNAs reached 0.964, 
which is significantly higher than those of the individual 
miRNAs. This result demonstrates that the combination of 
multiple plasma miRNAs is more accurate than individual 
miRNAs for RA diagnosis. Early studies evaluating 
miRNAs for use as biomarkers typically focused on 
individual miRNAs; however, the majority of recent 
studies tend to test the diagnostic value of miRNA panels 
in various human diseases. During the three stages of RA, 
Figure 4: Evaluation of the validated 9 miRNAs for the discrimination of RA patients from disease controls. The 
expression of 9 validated miRNAs in the plasma obtained from patients with RA (n = 75), OA (n = 18), SLE (n = 21), Graves’ disease (n = 
14) and HCs (n = 70) was determined by qRT-PCR. The bars denote the mean 2-Δcq values ± SD (*, P-values < 0.05 versus RA; #, P-values 
< 0.05 versus HC. ND, None detected. )
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which include autoimmune priming, tissue attack and 
chronic inflammation, there are many diverse, complex 
molecular events that may involve multiple miRNAs. 
Thus, multiple miRNAs, including joint tissue-specific 
miRNAs or miRNAs secreted by circulating blood cells, 
will be released into the circulation to form a specific 
plasma miRNA profile. Accordingly, these miRNAs may 
be screened and can serve as a biomarker panel for RA 
diagnosis. In this study, we compared the RA patients 
not only with HCs, but also with other disease controls, 
including OA, SLE and Graves’ disease. Together, levels 
of 4 miRNAs, including miR-122-3p, miR-3925-3p, miR-
342-3p and miR-4764-5p, were found to be statistically 
significant when compared with HCs and disease controls. 
Of note, the expression of miR-342-3p was specifically 
decreased in RA patients, indicating that miR-342-3p may 
serve as the best candidate biomarker for the diagnosis of 
RA.
The 9 plasma miRNAs identified in this study 
may be classified into two groups: an unknown function 
group (miR-4634, miR-4764-5p, miR-3926, miR-3925-
3p) and a known function group (miR-181d, miR-342-
3p, miR-122-3p, miR-9-5p, miR-219-2-3p). Although 
functional information on miRNAs in the former group 
is unavailable, our study demonstrates that miR-4764-
5p plasma levels correlate positively with RF, SJC, TJC 
and DAS28 but negatively with IL-13. In addition, miR-
4634 plasma levels correlated with all clinical features 
we examined with the exception of CRP. Further studies 
are required to identify the origin of these 4 plasma 
miRNAs and their target genes and the mechanisms 
regulating the biogenesis of these miRNAs. Although the 
plasma samples used for the array screening were from 
primary active RA patients, none of the 9 screened plasma 
miRNAs discriminated active RA from non-active RA. 
This unexpected result requires further confirmation in a 
larger cohort. Of the latter group, only two miRNAs, miR-
9-5p and miR-219-2-3p, correlated with both cytokines 
and chemokine as well as clinical parameters. Notably, 
miR-9-5p is mainly correlated with immune/inflammatory 
cytokines while miR-219-2-3p with clinical variables. 
Although miR-9-5p has been reported as oncogenic 
microRNA in non-small cell lung cancer, large B-cell 
lymphomas, osteosarcoma and breast cancer[29-32], little 
evidence shows inter-regulation between miR-9-5p and 
cytokines. Recent studies have shown that miR-219-2-
3p is associated with schizophrenia, diabetic retinopathy, 
acute inflammation and gastric cancer[33-37]. Thus, 
further studies are required to elucidate the possible 
mechanisms underlying the down-regulation and function 
of these two miRNAs in the peripheral blood of RA 
patients.
In summary, we have identified 9 differentially 
expressed plasma miRNAs in patients with RA that 
may serve as candidate biomarkers for RA diagnosis. In 
addition, several identified plasma miRNAs were found 
to be associated with clinical parameters, which may be 
implicated in the pathogenesis of RA disease. However, 
these data should be verified in a larger population of RA 
patients, and more importantly, functional experiments are 
required to validate the functional roles of these plasma 
miRNAs in RA pathogenesis.
MATERIALS AND METHODS
Study design
Three phases were designed to identify plasma 
miRNA profiles to act as potential biomarkers for RA 
(summarized in Figure 1). Briefly, in the initial biomarker 
screening stage, 10 plasma samples from 5 RA patients 
and 5 HCs were tested individually using the miRCURY™ 
LNA Array (version 18.0, Exiqon , Vedbaek, Denmark), 
a 7th-generation miRNA array containing 3100 capture 
probes, to identify miRNAs that were differentially 
expressed. In the second phase, differentially expressed 
miRNAs identified using the miRNA array were further 
selected using RT-qPCR in a small set of individual plasma 
samples (18 RAs and 14 HCs, selection phase). The 
selected miRNAs were then validated in a large number of 
individual samples from 75 RA patients and 70 HCs using 
qRT-PCR. A disease control cohort included 18 patients 
with OA , 21 patients with systemic lupus erythematosus 
(SLE) ), 14 patients with Graves’ disease. All of the 
study protocols and consent forms were approved by the 
Affiliated Hospital of Jiangsu University. All participants 
provided written informed consent to participate in this 
study.
Plasma preparation, RNA isolation
Whole blood (2 mL) was collected from each 
subject, and plasma was separated by centrifugation 
at 1600 g for 10 min at room temperature followed by 
centrifugation at 16,000 g for 10 min at 4°C to remove 
all cell debris. The plasma supernatant was collected and 
stored at -80°C until further analysis. 
For the miRNA array test, total plasma RNA was 
harvested using TRIzol (Invitrogen, Carlsbad, CA, USA)) 
and a miRNeasy Mini Kit (Qiagen, Valencia, CA, USA) 
according to manufacturer’s instructions. For the RT-qPCR 
assay, total RNA was extracted from 200-µl volumes 
of plasma using the mirVana™ PARIS™ Kit (Ambion, 
Foster City, CA, USA) according to the manufacturer’s 
instructions. Two synthetic Caenorhabditis elegans 
miRNAs, cel-miR-39 and cel-miR-238 (synthesized by 
Ribobio, Guangzhou, China), which lacked sequence 
homology to human miRNAs, were added to each 
denatured sample (after plasma was mixed with denaturing 
buffer) to normalize the sample-to-sample variation. 
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miRCURY™ LNA array
The plasma miRNA expression profiles of 5 
RA patients and 5 HCs were determined using the 
miRCURY™ LNA Array. RNA quantity was tested using 
a NanoDrop 1000, and the samples were then labeled 
using the miRCURY™ Hy3™/Hy5™ Power labeling 
kit and hybridized onto the miRCURY™ LNA Array. 
Following washing steps, the slides were scanned using 
an Axon GenePix 4000B microarray scanner. Scanned 
images were then imported into GenePix Pro 6.0 software 
(Axon Instruments , Foster City , CA) for grid alignment 
and data extraction. Replicated miRNAs were averaged, 
and miRNAs with intensities ≥30 in all samples were 
chosen for calculating the normalization factor. Data on 
miRNA expression were normalized using the median 
normalization protocol. Following normalization, 
significantly differentially expressed miRNAs were 
identified via Volcano Plot filtering. Finally, hierarchical 
clustering was performed using MEV software (v4.6, 
TIGR) to show distinguishing miRNAs among the 
samples.
Determination of plasma miRNA by qRT-PCR
Two micrograms of total RNA were reverse-
transcribed using a commercial kit (Promega, Madison, 
WI, USA) according to the manufacturer’s protocol. 
Briefly, the 50-μl reactions were incubated for 60 min 
at 42°C and 10 min at 70°C and were then stored at 
4°C. Real-time PCR analysis was performed using an 
Applied BioSystems 7500 Thermocycler according to 
manufacturer’s protocol with SYBR Green PCR Master 
Mix (TaKaRa, Daliang, China). In short, the reactions 
were incubated at 95°C for 20 s, followed by 40 cycles 
of 95°C for 10 s and 60°C for 34 s. A dissociation stage 
was performed at the end of the amplification procedure 
to determine potential non-specific amplifications. Reverse 
transcription and qPCR were performed using a Bulge-
Loop™ miRNA qPCR Primer Set (RiboBio, Guangzhou, 
China). The relative expression level of each miRNA 
was calculated using the comparative Cq (quantification 
cycle) method. To avoid possible differences due to 
amount of starting RNA, the resultant miRNA levels were 
normalized to the mean of cel-miR-39 and cel-miR-238. 
Data were analyzed using SDS Relative Quantification 
Software version 2.06 (Applied BioSystems , CA, USA).
Cytokine and chemokine assays
The Human Th1/Th2/Th9/Th17/Th22 13plex 
FlowCytomixTM kit and the Human Chemokine 6plex 
FlowCytomix kit from eBioscience (San Diego, CA, 
USA) were used to quantitatively measure levels of 
interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-17A, interferon 
(IFN)-γ, tumor necrosis factor (TNF)-α, macrophage 
inflammatory protein (MIP)-1β, monocyte chemoattractant 
protein (MCP)-1, MIP-1α, IL-8 and chemokine (C-X-C 
motif) ligand 9 (CXCL9) in plasma according to the 
manufacturer’s instructions.
Data analysis and statistics
All expression values of plasma miRNAs were 
normalized to cel-miR-39 and cel-miR-238 and were 
then expressed as 2-ΔCq, in which ΔCqmiR = CqmiR-(Cq 
cel-miR-39
+Cq
cel-miR-238
)/2. The miRNA data are presented 
as the means ± standard errors (SEs). For continuous 
data, comparisons between groups were performed 
using Student’s t tests (two groups) or analyses of 
variance (ANOVAs) ( >2 groups) for Gaussian data and 
using Mann-Whitney U tests (two groups) or Kruskal-
Wallis tests (> 2 groups) for non-normally distributed 
data. Pearson’s correlation analysis was used to assess 
relationships between plasma miRNA expression and 
chemokine and cytokine levels and the patients’ clinical 
characteristics. Receiver-operator characteristic (ROC) 
curves and area under the curve (AUC) analyses were used 
to determine the sensitivity, specificity and corresponding 
cut-off values for each miRNA. Logistic regression 
was used to develop composite panels of biomarkers to 
identify a panel that could distinguish RA from control 
with the greatest sensitivity and specificity. A p-value was 
considered significant when less than 0.05. Statistical 
analyses were performed using SPSS software version 
16.0. 
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